Seres Therapeutics Inc Stock Price, News & Analysis

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Paula Cloghessy as Executive Vice President and Chief People Officer effective February 7, 2022. Her extensive 20+ years in HR within biotechnology and pharmaceuticals aims to enhance the company’s culture and support its growth, particularly in advancing SER-109 towards FDA approval. Cloghessy emphasizes talent development and employee engagement, ensuring a positive work environment. This strategic hiring comes as Seres continues its pioneering efforts in microbiome therapeutics.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a webcast investor event on January 31, 2022, from 8:30 a.m. to 10:00 a.m. ET, focusing on microbiome therapeutics for infection protection. Clinical data from the Phase 3 ECOSPOR III trial showed that SER-109 significantly reduced CDI recurrence, with 88% of patients achieving a sustained clinical response. Additionally, SER-155 is being evaluated in patients at risk of serious infections. The event will feature discussions on new infection prevention strategies and the role of microbiome therapeutics.

Seres Therapeutics (MCRB) announced significant results from its Phase 3 ECOSPOR III study on SER-109, an oral microbiome therapeutic for recurrent C. difficile infection. The study demonstrated an 88% sustained clinical response in patients taking SER-109, compared to 60% with placebo. Furthermore, SER-109 was well tolerated, mirroring placebo safety profiles. The company plans to finalize its Biologics License Application (BLA) filing by mid-2022, aiming for FDA approval. These findings published in the New England Journal of Medicine highlight SER-109's potential to transform treatment standards for rCDI.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 8:15 a.m. ET. A live audio webcast will be available on the company's website, with a replay accessible one hour post-event for 21 days. Seres focuses on microbiome therapeutics, showcasing its SER-109 program, which received Breakthrough Therapy and Orphan Drug designations from the FDA for treating recurrent C. difficile infections. Additionally, SER-301 and SER-155 are under evaluation in clinical studies for ulcerative colitis and gastrointestinal infections.

Seres Therapeutics (NASDAQ: MCRB) reported preliminary findings from the Phase 2b ECO-RESET study of SER-287 for treating ulcerative colitis, revealing successful engraftment of bacterial species. Despite the primary endpoints not being met, engraftment results were statistically significant (p ≤ 0.001). The company is exploring potential biomarker-based patient selection for future trials. Ongoing analysis of SER-287 and SER-301 data is expected to guide further development steps in ulcerative colitis.

Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced the enrollment of the first patient in its SER-155 Phase 1b clinical study, aimed at reducing infections, mortality, and graft-versus-host disease (GvHD) in patients undergoing hematopoietic stem cell transplantation (HSCT). SER-155, a microbiome therapeutic, targets antibiotic-resistant infections and aims to enhance microbiome diversity to improve patient outcomes. Collaborating with prestigious institutions like Memorial Sloan Kettering Cancer Center and The University of Chicago, the trial will assess both safety and effectiveness in approximately 70 patients.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that President and CEO Eric Shaff will be participating in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The chat will be available for on-demand viewing on the company’s website. Seres is at the forefront of microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for treating recurrent C. difficile infection and receiving FDA Breakthrough Therapy designation. The company is also advancing additional programs for ulcerative colitis and gastrointestinal infections.

Seres Therapeutics (MCRB) announced completion of enrollment in its SER-109 recurrent C. difficile infection open-label study. The company anticipates filing a Biologics License Application (BLA) in mid-2022, pending Phase 3 results and safety data. Collaborations with Nestlé Health Science and Bacthera A.G. boost commercialization prospects for SER-109. Financially, Seres reported a net income of $68.2 million for Q3 2021, significant growth from a loss of $30.3 million in 2020. R&D expenses rose to $39.9 million, reflecting ongoing clinical development efforts.

Bacthera and Seres Therapeutics have announced a collaboration to manufacture SER-109, a lead product for recurrent Clostridioides difficile infection (rCDI). The partnership includes establishing a dedicated facility at Bacthera's new Microbiome Center of Excellence in Switzerland. This agreement aims to enhance commercial production capacity and support the manufacturing process, leveraging Bacthera's infrastructure while addressing the significant health threat posed by rCDI, responsible for high hospitalizations and deaths in the U.S.